Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,871 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate Control Clear all
Terminated Not applicable Interventional Results available

LoBAG30 Diet in Patients on Metformin

NCT00607867
View directory record Official record
Conditions
Diabetes Mellitus, Diet
Interventions
LoBAG30 diet, Control Diet
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 30, 2026, 6:26 AM EDT
Recruiting Not applicable Interventional

Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes

NCT05899166
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Ketogenic diet, food delivery and education, Standard diet, food delivery and education
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 12 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 1 Interventional

Improving Outcomes In Diabetic Patients During CABG Surgery By Optimizing Glycemic Control

NCT00460499
View directory record Official record
Conditions
Glycemic Control
Interventions
A IV Insulin drip, B Low Dose GIK, C High Dose GIK
Drug
Lead sponsor
American Heart Association
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

NCT03279393
View directory record Official record
Conditions
PTSD, Trauma, Healthy
Interventions
fluorodeoxyglucose (FDG)-PET/MRI
Drug
Lead sponsor
Zahi Fayad
Other
Eligibility
30 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Consumer Perceptions of Alcoholic Beverages

NCT07226271
View directory record Official record
Conditions
Health Behavior
Interventions
Natural Claim, Sugar Claim, Fruit Claim
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 99 Years
Enrollment
1,534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 30, 2026, 6:26 AM EDT
Not yet recruiting Not applicable Interventional

Using Wearable Sensors To Understand Low Blood Sugar in Type 1 Diabetes

NCT06727071
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hyperglycemic clamp
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 30, 2026, 6:26 AM EDT
Recruiting Not applicable Interventional

Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or Obesity

NCT07853898
View directory record Official record
Conditions
Obesity / Overweight
Interventions
Pistachio Co-consumption, Refined-Carbohydrate Control Co-consumption
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 35 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epithelial Healing and Visual Outcomes Using Omega-3 Therapy Before and After Photorefractive Keratectomy (PRK) Surgery

NCT01059019
View directory record Official record
Conditions
Refractive Error
Interventions
Omega-3 Fatty Acid Supplements
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 28 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Oct 30, 2026, 6:26 AM EDT
Recruiting Phase 2 Interventional

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

NCT03835767
View directory record Official record
Conditions
Milk and/or Peanut Allergy
Interventions
Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk)
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 6:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Small Extracellular Vesicles and Insulin Action

NCT05933707
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolically Healthy Obesity, Obesity, Metabolically Benign
Interventions
People with Metabolically Unhealthy Obesity - Low Calorie Diet
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
25 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease

NCT00359944
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AC-3933, Sugar Pill
Drug · Other
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
34
States / cities
LIttle Rock, Alaska • Phoenix, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 30, 2026, 6:26 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The Influence of Daily Strawberry Intake on Vascular Health in Elderly Men

NCT04763499
View directory record Official record
Conditions
Vascular Dilation
Interventions
freeze dried strawberry powder
Other
Lead sponsor
University of California, Davis
Other
Eligibility
60 Years to 80 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carbohydrates and Children

NCT03185884
View directory record Official record
Conditions
Carbohydrate Metabolism
Interventions
Control, Experimental
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
9 Years to 13 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

Naturlose (D-Tagatose) Efficacy Evaluation Trial

NCT00955747
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tagatose, Sugar Substitute Splenda
Drug
Lead sponsor
Robert Lodder
Industry
Eligibility
18 Years to 75 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Hueytown, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

NCT00899847
View directory record Official record
Conditions
Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions
Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone
Procedure · Drug · Radiation + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 4 Interventional

To Investigate the Role of Upstream High Dose Statin in STEMI

NCT01050348
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Atorvastatin calcium, Inactive Placebo
Drug
Lead sponsor
The Western Pennsylvania Hospital
Other
Eligibility
25 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Oct 30, 2026, 6:26 AM EDT
Terminated Phase 3 Interventional

Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes

NCT01029444
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years to 85 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT03355209
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Endogenous Oxalate Synthesis

NCT05229952
View directory record Official record
Conditions
Healthy, Kidney Stone, Obesity
Interventions
Low-oxalate controlled diet, Primed, continuous intravenous infusion of 13C2-oxalate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 30, 2026, 6:26 AM EDT
Enrolling by invitation Phase 4 Interventional

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes
Interventions
Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT02238626
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo (for MN-166), MN-166, riluzole
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 30, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

NCT01064414
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
25 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Concord, California • Fountain Valley, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 30, 2026, 6:26 AM EDT